



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Rolufta Ellipta

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	Outcome:	04/08/2026		SmPC,	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000361527	C. Safety, efficacy, pharmacovigilance changes - C.z Other variation - Accepted C.z (Type IB) – To implement editorial changes to the product information, including: (1) removal of the UK (NI) from the list of local representatives in the PL in accordance with the Windsor Framework; (2) inclusion of the postcode in the MAH address; and (3) typographical corrections, formatting updates, and other changes in line with the most recent QRD template. In addition, the MAH corrected the product name in the PT product information.			Labelling and PL	
Variation type IB / EMA/VR/0000327245	Outcome: This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Q.I.b.2 Change to analytical procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Q.I.b.2.z Other variation - Accepted	23/04/2026			
Variation type IA / EMA/VR/0000308349	Outcome: B.I.b.2 Change in test procedure for active substance or starting	28/11/2025			

	material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Refused				
Variation type IA / EMA/VR/0000278132	Outcome: B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.i Introduction of a new site of micronisation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted	31/07/2025			
PSUR / EMA/PSUR/0000268992	EURD: PSUSA/00010263/202412 Active substance: umeclidinium Outcome: Maintenance	04/09/2025			Maintenance

--	--	--	--	--	--